Author: acn

HONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - With the national strategy of “new quality productive forces” driving high-quality development, Yee Hop Holdings Limited (“Yee Hop Holdings”; stock code: 1662.HK) subsidiary Absolute Pure EnviroSci Limited (“APEL” or “the Company”) is actively aligning with national policies. It has recently established a Microfactory in collaboration with the Hong Kong Productivity Council (“HKPC”) to industrialize the patented Wisepura Aquapura porous silica capsule technology in Hong Kong, promoting smart manufacturing and new industrialization. The HKPC’s Life & Health Tech Hall, which opened in March this year, showcases over 20 research achievements and innovative applications developed by the HKPC, InnoHK, local universities, and industry partners, including the patented Wisepura Aquapura porous silica capsule technology.The World’s First Wisepura Aquapura Microfactory Fully OperationalAs a significant achievement of the collaboration, the world’s first Wisepura Aquapura Microfactory, developed in collaboration between APEL and HKPC, was officially launched on 13 June 2025 in Kowloon Bay, Hong Kong. This marks the successful implementation of the first phase of “Industry 4.0” and a significant milestone in the industrialization of APEL’s research achievements. During the inauguration ceremony, attended by numerous guests from the investment and business sectors, Mr. Jackin Jim, Chairman of Yee Hop Holdings, Dr. David Chung, Chairman of APEL, and Dr. Pat Yeung, Director of APEL, jointly unveiled the Microfactory, officially announcing its commencement of operations.Dr. Pat Yeung, Director of APEL (first from the left), Mr. Jackin Jim, Chairman of Yee Hop Holdings (second from the left), Mr. Mohamed Butt, Executive Director of HKPC (second from the right), and Dr. David Chung, Chairman of APEL (first from the right) are pictured together at the Wisepura Aquapura Microfactory Inauguration Ceremony.Dr. David Chung, Chairman of APEL, said, “We are honored to collaborate with HKPC in establishing the Wisepura Aquapura Microfactory, and we would like to extend our heartfelt gratitude to HKPC for their support. This collaboration highlights our strong research and innovation capabilities in the field of life and health technology. The official commencement of production at the APEL Wisepura Aquapura Microfactory enhances our ability to meet the growing market demand and injects new momentum into the company’s development. Looking ahead, we will continue to expand our network of partners and actively pursue international opportunities, endeavoring to bring local research achievements to the global stage and contribute to global health and environmental protection, working together for a sustainable future.”Dr. David Chung, Chairman of APEL, delivers a speech at the inauguration ceremony.Establishes Strategic Partnership with Shanhu Group to Explore New Opportunities in Water Purification and Aquaculture Technology in the Greater Bay AreaGuangdong Shanhu Group Co., Ltd. (“Shanhu Group”), a global leader in indoor air environment solutions, has seen its core product, industrial fans, gain widespread popularity across six continents, serving over 50 million users. Since 2015, Shanhu Mechanical and Engineering Co., Ltd., a subsidiary of Shanhu Group, has taken a forward-looking approach in the research and development (R&D) of intelligent and energy-saving technologies for aquaculture machinery. On 13 June 2025, APEL officially signed a strategic Memorandum of Understanding (MoU) with Shanhu Group to jointly enter the water purification and intelligent aquaculture sectors. The collaboration aims to develop advanced solutions for high-demand applications such as water purification equipment, ecological restoration technologies, and smart monitoring systems. These innovations will target environmental projects including river remediation, black and odorous water treatment, and ecosystem rehabilitation. Additionally, the partnership will address the stable demand for new filtration materials, water treatment processes, and water quality monitoring technologies in municipal wastewater treatment plants and industrial park facilities. The two companies will also establish cooperative relationships with government environmental agencies and municipal engineering firms to participate in wastewater treatment project bids and provide customized solutions.The collaboration encompasses technological R&D, market expansion, and resource sharing. The two parties will jointly develop intelligent water quality monitoring systems, leveraging big data and artificial intelligence (AI) to optimize aquaculture decision-making while promoting high-efficiency purification technologies for environmental engineering and municipal wastewater treatment markets. The project will integrate Shanhu Group's expertise in electromechanical equipment and disinfection technologies with APEL's proprietary Wisepura Aquapura Microfactory water treatment solutions. This one-year agreement, renewable upon expiration, will initially focus on deploying the collaborative achievements in the Guangdong-Hong Kong-Macao Greater Bay Area through business and technical exchange forums. The partnership is expected to drive the advancement of environmental protection and aquaculture industries in the region, fostering industrial chain transformation. Looking ahead, the collaboration aims to gradually expand into overseas markets.APEL (left) and Shanhu Group sign a strategic Memorandum of Understanding.Advancing towards a new era of “Industry 4.0” with smart manufacturingIn advancing “Industry 4.0” initiative, the APEL Wisepura Aquapura Microfactory integrates cutting-edge technologies such as physical AI, the Internet of Things, and big data into its manufacturing processes. This enables smart monitoring and automated management, enhancing overall operational efficiency and product quality. To mitigate the impact of rapid temperature increase during mixing on the structural integrity and performance of the smart silica capsules, the factory has installed a customized smart temperature control system powered by physical AI to ensure stable product quality. The factory is also equipped with a human-machine interface (HMI), programmable logic controllers (PLCs), and clean-in-place (CIP) systems to boost production efficiency and flexibility. Additionally, it features an Industrial Internet of Things (IIoT) monitoring system to track change of temperature and volume and electricity usage in real time, optimizing energy management. It also adopts just-in-time (JIT) production management to reduce inventory backlog and resource waste, comprehensively promoting efficient smart manufacturing operations.By implementing lean management and the principles of smart manufacturing, APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization within a limited space. This achievement enables flexible small-batch customized production and achievies “Industry 4.0 1i Maturity,” paving the way for physical AI applications.Guests visiting the APEL Wisepura Aquapura Microfactory.Dual Advancement in Health and Environmental Technology InnovationWater is an essential resource for sustaining human life and ecological health. However, urban development has exacerbated water pollution, posing significant threats to public health and ecosystems. To address these challenges, APEL has developed Wisepura Aquapura, featuring the world’s first patented porous silica capsule technology. This innovation has received gold and silver medals at the International Exhibition of Inventions of Geneva in 2022 and 2024, respectively. It intelligently releases active ingredients upon contact with water, effectively eliminating over 95% of harmful microorganisms and antibiotic-resistant bacteria while also meeting diverse application needs. This technology has been widely applied across Hong Kong’s public infrastructure, targeting over 30 types of bacteria, fungi, and viruses in water supply, air conditioning, and sewage systems—including Legionella, hand-foot-and-mouth disease pathogens, influenza virus, and Candida albicans—significantly reducing the risk of waterborne and aerosol-transmitted diseases. Moreover, the silica capsule can be reused multiple times and safely disposed of at the end of its lifecycle, thereby minimizing environmental impact and setting a new standard for water treatment solutions.APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization, achieving “Industry 4.0 1i Maturity.”About Wisepura Aquapura MicrofactoryLocated in Kowloon Bay, the APEL Wisepura Aquapura Microfactory scales up laboratory processes to pilot production while effectively adapting to the spatial constraints of traditional multi-story industrial buildings in Hong Kong. It achieves a high production capacity of 6 tons per day. At the heart of the production line is its C-shaped layout, laying a solid foundation for efficient operations. The factory is equipped with mixing, filling, and screw capping systems, along with smart technologies, and a customized pipeline system that connects 5 pharmaceutical-grade mixing tanks, enabling comprehensive lean management. Due to the limited space, the factory is equipped with a 2.5-meter-high automatic capping machine that maximizes vertical space, demonstrating the perfect integration of space efficiency and smart technology.The launch of the Microfactory not only significantly enhances production efficiency but also accelerates APEL’s collaboration with Superpower Pumping Engineering Co., Ltd., facilitating the market expansion of research products. Furthermore, the Microfactory has received official orders from the Drainage Services Department, demonstrating strong recognition of its solutions and generating tangible economic benefits for the Company. To tap into the Japanese market, which places high value on personal health and environmental hygiene, APEL is currently holding an innovative interactive exhibition at The Lab. in Osaka to showcase its three flagship products—Wisepura water and air purification systems, GERMAGIC™ antimicrobial coating, and GERMAGIC™ PET health care solutions for pets—seizing growth opportunities in Asia’s health technology industry.About Yee Hop Holdings LimitedYee Hop Holdings Limited (stock code: 1662.HK) is a company listed on the Main Board of the Stock Exchange of Hong Kong Limited and a long established contractor in Hong Kong, principally engaged in the provision of foundation works and tunneling works. In addition, its associate company, Windmill Street Development, is engaged in the development of premium property projects in Birmingham, the United Kingdom. In 2023, the Group established Absolute Pure EnviroSci Limited (“APEL”), which focuses on health and environmental innovations, including the distribution and research and development of specialty biochemical and biomedical products. APEL has also established laboratories in collaboration with The Hong Kong University of Science and Technology (“HKUST”) and the Hong Kong Science Park successively. The joint laboratory, “HKUST-AP EnviroSci Ltd. Joint Laboratory on Health and Environmental Innovation,” was officially launched on 10 January 2024. Additionally, the “APEL Biomedical Technology Innovation and Translational Commercial Laboratory” located at the Hong Kong Science Park was officially inaugurated on 13 March 2024.For more information about Yee Hop Holdings, please visit: http://www.yee-hop.com.hk/About Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited (“APEL”), is an indirect non-wholly owned subsidiary of Yee Hop Holdings Limited, a company listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 1662.HK). With a mission to improve the quality of life and living environments, APEL is principally engaged in the research and development and commercialization of health and environmental innovations. Leveraging its Multilevel Antimicrobial Polymer (MAP-1) technology, APEL has developed specialized application formulas in four key areas: air purification in aircraft, water purification, livestock health, and eco-friendly building materials, all designed to address pressing global challenges. APEL looks forward to working with researchers and industry partners worldwide to drive further health and environmental innovations.For more information about APEL, please visit: https://apesl.com/For media inquiries, please contact:AJA (IR & Communications)Avy YuTel: +852 9500 4443Email: avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 7.4% to HK$1,576.9 million- Profit from continuing operations rose by 43.1% to HK$300.8 million- Net gearing ratio down to 8.3% from 12.2%- Recommended Final Cash Dividend of HK5.50 Cents Per Share and Special Cash Dividend of HK6.00 Cents Per Share- Continued enrichment of pipeline through R&D and strategic in-licensing- Improved operational efficiency by enhancing capacity and optimizing production leverage efficiencyHONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Building on the growth momentum of previous years, Jacobson Pharma continued to make promising progress, achieving total revenue of approximately HK$1,576.9 million during the Reporting Period, a year-on-year growth of 7.4%. Profit for the year from continuing operations increased by 43.1% to HK$300.8 million, reflecting the Group’s steadfast commitment to strategic execution and operational excellence.The Group’s financial position remains strong, providing a solid foundation for fuelling future development and dividend returns to shareholders. Bolstered by a robust business performance and persistent cost management, the Group achieved an adjusted EBITDA of HK$572.8 million. Net gearing ratio improved to 8.3% from 12.2% at the close of FY2025, and cash reserves held steady at HK$509.0 million.The Board recommends the payment of a final cash dividend of HK5.50 cents per share (FY2024: HK3.00 cents per share) and a special cash dividend of HK6.00 cents per share (FY2024: Nil). Including the interim cash dividend of HK3.50 cents per share already paid, the total cash dividend for FY2025 would be HK15.00 cents per share (FY2024: HK5.50 cents per share), up by 172.7% year-on-year.Robust Portfolio Meets Rising Healthcare DemandThe Group’s sales growth in FY2025 was driven by multiple factors. Hong Kong’s extended flu season, compounded by circulating respiratory pathogens, led to a significant surge in demand for cold and flu treatments. Broader healthcare trends further supported this momentum, including an aging population, high rates of chronic conditions like diabetes and hypertension, and growing mental health needs. Additionally, public health initiatives heightened awareness of preventive care, reinforcing demand for medications and medical consultations. Together, these trends contributed to sustained sales momentum across the Group's businesses throughout the Reporting Period.The Group remains well-positioned to meet Hong Kong’s growing healthcare needs with its broad portfolio of essential medicines and specialty drugs. Backed by an efficient supply chain, it ensures reliable access to cost-effective treatment choices while reinforcing its role as a trusted healthcare service provider.Sustained R&D Momentum and Specialty Portfolio ExpansionMomentum in expanding the Group’s R&D pipeline of the Group was sustained throughout the Reporting Period, advancing its strategy to broaden the product portfolio. As of 31 March 2025, the pipeline comprised 219 products at various development stages.To expand its specialty drugs portfolio, the Group concluded various in-licensing agreements with global manufacturers for 20 high-performing products across key therapeutic areas such as immunology, oncology, cardiology, neurology, and rare diseases. Selected for their strong clinical profiles and market potential, these additions support sustained growth and reflect the Group’s commitment to advancing patient care through innovative therapies.Bringing Innovation to Enhance Patient OutcomesThe Group continues to expand market reach for Arsenic Trioxide Oral Solution, co-developed with The University of Hong Kong to treat acute promyelocytic leukaemia (APL). Clinical trials show a 97% survival rate and 100% molecular remission, earning it the Orphan Drug Designation from both the U.S. FDA and EMA. A global Phase III trial will be launched in 2026 with market approval targeted for 2028.Jacobson Pharma also achieved a significant milestone on 20 February 2025, with the launch of supply chain liaison services for Axicabtagene Ciloleucel (Yikaida) – a CAR-T therapy - in partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun Kairos Biotechnology Inc.. Supported by an Advanced Therapeutic Product (ATP) logistics license, this breakthrough therapy for diffuse large B-cell lymphoma marks a major advance in next-generation cancer care.Powering Growth with Smart ProductionIn line with the Groups’ strategic goal of enhancing its manufacturing capabilities, Jean Marie Pharmacal Co Limited, a member of the Group, commenced the development of a new pharmaceutical facility at Tai Po InnoPark in February 2025. Supported by the Hong Kong Government’s New Industrialisation Acceleration Scheme, the facility will house 10 smart production lines for sterile eye drops, solid dosage forms, and oral liquids. Leveraging AI, robotics, and real-time analytics, the advanced facility will boost production efficiency and quality standards. Trial production is slated for late 2026, with a focus on developing specialty products to cater to unmet medical needs. This investment strengthens the Group’s industry leadership and supports Hong Kong’s emergence as a hub for advanced pharmaceutical manufacturing.Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, stated, “FY2025 has been another eventful year for Jacobson Pharma, underscoring the strength of our strategy, the dedication of our team, and the trust of our stakeholders. These foundations continue to position us as a leading force in Hong Kong’s generic pharmaceutical sector.Looking to 2026, we remain optimistic about our prospects and growth. Healthcare policy reforms and rising medication demand from an aging population and chronic conditions will fuel the growth of the generic drugs market. With a strong pipeline, expanding partnerships, and digital innovation, we are well-positioned to seize growth opportunities and create sustainable values for the Group’s businesses”About Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 9 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group is committed to strategically enhancing its portfolios by introducing high-value-added specialty products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com Copyright 2025 ACN Newswire via SeaPRwire.com.

PIONEERTOWN, CA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - ESCAPE Records releases two transcendent works from its secretive Mojave Desert hub in Pioneertown CA: the Parallel Universe EP, a genre-defying musical odyssey from touring electronic artists and industry veterans, and Gong Song! (Live from Escape, Pioneertown CA), a 45-minute sound healing masterpiece by Alessandra Montana.Naturally Occurring Emoji - BEEPLEEveryday from BEEPLE. Cover of Parallel Universe EP. Courtesy of Escape Records LLC.Crafted where social media fades to the obscure and creativity thrives, these two new records aim to forge deep audience connections - inspiring a sense of solidarity between the creative and their audience.The Parallel Universe EP blends electronic, Americana, and Latin vibes, born during a songwriting retreat at ESCAPE's legendary studio, some 40 miles from the gates of Coachella in the high desert of California, a mile above sea level under a myriad of stars. Listeners are invited to ponder what their life would be like in a parallel universe; evoking poignant emotions in today's somewhat turbulent world.Tracks are shared by studio founder and producer ROC Gardner, Latin Grammy-nominated Cimafunk (La Vida), Jamie N Commons (Hold Me While You Wait), DJ Tennis (Life and Death), and Grammy-nominated Jan Blomqvist (Remote Control), joined by producers Joseph Ray (Nero), Daniel Cantisani, Nikko Gibler (RicoshÄ“i), and Devlin Thorn alongside artists that include Kim Bullard (Elton John) and Craig McClune (David Gray) who lent their expertise to evolving the tracks.Mixed by Mick Guzauski (Daft Punk, The Weeknd, Michael Jackson) and mastered by Bernie Grundman, tracks include Mezcalita (June 13), Happy Unhappy (June 20), La Sugar (June 27), and Never Know (July 4). BEEPLE's surreal artwork Naturally Occurring Emoji and an AI-driven video by The Dor Brothers amplify the EP's cosmic narrative."The universal sky we spent each night under sparked something raw," says ROC. "It was awesome breaking out of our channels - we got to capture all these ideas, unbound by trends or any other concerns - it was great fun!"Simultaneously, Alessandra Montana's Gong Song! (Live from Escape) captures a live 45-minute sound journey, recorded meticulously with vintage gear and microphones at ESCAPE. Guided by mixing engineer Rob Columbus and mastered by Grundman, Montana's gongs and sacred instruments weave a meditative portal for healing."Escape's magic let me share my practice globally. I can't wait for people to hear this and experience the journey we went on," says Montana.ESCAPE, a 140-acre creative haven hosting Rüfüs Du Sol, Arctic Monkeys, Usher, RAYE - and many others - fosters unfiltered artistry. The studio hopes to deliver magic - and its music - unfettered and unfiltered.Visit www.esca.pe for more.Assets: Press release, artwork, lyrics, .wav files available upon request.Interviews: info@esca.peJan Blomqvist appears courtesy of Armada Music B.V.Tracks:Mezcalita (1st Single): https://audiosalad.ffm.to/commons-roc-mezcalitaParallel Universe EP: https://audiosalad.ffm.to/parallel-universeGong Song! (Live from Escape): https://audiosalad.ffm.to/gong-songContact InformationSteven Bradley9/9 - Digital/Social Mediaescape@9slash9.comEscape RecordsLabel Contactinfo@esca.peSOURCE: Escape Records LLC Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 达丰设备服务有限公司（"达丰"或"公司"，连同其附属公司统称"集团"）（股份代号：2153）为在中国成立的首家外资塔式起重机服务供应商，公布其截至2025年3月31日止年度（"2025财年"或"年内"）的全年业绩。2025财年，集团的收益为人民币634.6百万元（2024财年：682.3百万元）。公司权益持有人应占亏损为人民币120.5百万元（2024财年：95.6百万元）。亏损增加主要是由于于(i)经济增长放缓及建筑业不景气导致收入下降；及(ii)递延税项调整导致所得税开支增加。截至 2025 年 3 月 31 日，集团全年平均管理的塔式起重机总数为1,180台。集团的使用总吨米由截至2024年3月31日止年度的3,178,404减少至截至2025年3月31日止年度的3,137,910。于2025年3月31日，集团有256个在建项目，未完成合同总价值约为人民币721.4百万元，手头项目共有38个，预计合同总价值约为人民币78.7百万元。于本财政年度内，在市场需求不足及塔式起重机每吨米平均每月服务价格下降的影响下，供需失衡导致整个工程机械行业面临激烈的市场竞争。为应付市场疲弱情况，集团因时制定不同战略，并不断地调整业务占比，逐年降低房地产行业的收入占比。集团积极回应国家提出的大力发展清洁能源的号召，并应市场发展趋势及发展潜力，专注于火电项目和核电项目。而清洁能源项目施工期长，规模大，集团依靠丰富的行业经验，成熟的施工技巧以及雄厚的技术实力取得相当的优势。于2025财年，集团加快推进境外市场的布局，通过大湾区和印尼深入贯彻集团运营策略，逐步扩大大中型塔式起重机机队。截止目前，香港和印尼的项目多半为大吨米塔机。由于以上原因，清洁能源和境外项目依旧是集团未来的发展重点。年内，集团继续投资于数字化管理平台及新的塔式起重机技术解决方案的研发。于2025年3月31日，集团拥有187项塔式起重机相关的实用新型及发明注册专利。雄厚的技术实力将继续助力集团获得项目，而在塔式起重机技术解决方案方面的研发能力提升将增强集团交付卓越服务的能力。达丰设备服务有限公司行政总裁邱国燊先生表示："除了房地产市场和建筑行业的低迷外，地缘政治紧张局势和人民币贬值压力进一步削弱了中国经济。为应对这些经济挑战和瞬息万变的营商环境，我们迅速调整了发展战略，包括拓展清洁能源建筑领域，并将地域范围扩展至大湾区及印尼。我们相信，这些举措的积极影响将在未来几年逐步显现。"达丰设备服务有限公司主席黄山忠先生总结："即使身处最艰难的环境，我们始终坚守初心。秉承'厚德、安全、卓越'的核心价值观，我们将在业务发展中持续追求卓越。在下一财年中，我们将进一步巩固在清洁能源及新市场的优势地位，把握市场新机遇，同时专注于塔式起重机新技术的研发，使我们具备最强大的技术能力，为客户提供卓越的服务。此外，我们还将持续推进资源共享及降本增效等举措。透过上述措施，我们相信，我们能够实现集团的企业愿景'做最好的建筑设备服务供应'。" Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 随着国家「新质生产力」成为推动高质量发展的重要策略，义合控股有限公司（「义合控股」；香港主板上市编号：1662）旗下附属公司 Absolute Pure EnviroSci Limited（「APEL」或「本公司」）积极响应国家政策，携手香港生产力促进局（「生产力局」）共同建设智能微工厂，在香港实现Wisepura Aquapura多孔结构硅微囊专利技术产业化，推动香港智能制造和新型工业化。今年 3 月开幕的生产力局「生命健康科技馆」展示了逾 20 项由生产力局、InnoHK研发平台、本地大学及业界携手研发的科技成果及创新应用，包括Wisepura Aquapura多孔结构硅微囊专利技术。全球首个Wisepura Aquapura智能微工厂全面投入生产运营作为双方合作的重要成果，APEL 与生产力局合作建设的全球首个Wisepura Aquapura智能微工厂于 2025 年 6 月 13 日香港九龙湾正式启用，标志着「工业 4.0」的第一阶段正式落地和 APEL 科研成果产业化发展的重要里程碑。在投资界和商界众多嘉宾的见证下，义合控股主席詹燕群先生、APEL 主席钟伟强博士及 APEL 董事杨学光博士于启用典礼上共同为 APEL Wisepura Aquapura智能微工厂揭幕，正式宣告其投入生产运营。APEL 董事杨学光博士（左一）、义合控股主席詹燕群先生（左二）、生产力局总裁毕坚文先生（右二）及APEL 主席钟伟强博士（右一）于Wisepura Aquapura智能微工厂启用典礼合照。APEL 主席钟伟强博士表示：「我们非常荣幸可以与生产力局合作建设Wisepura Aquapura智能微工厂，并衷心感谢生产力局对 APEL 的支持，充分印证了我们在生命健康科技领域深厚的科研实力与创新能力。APEL Wisepura Aquapura智能微工厂的正式投产，提升了我们应对市场日益增长需求的能力，为公司发展注入新动能。展望未来，我们将持续拓展合作伙伴网络，积极拓展国际版图，致力将本地科研成果推向全球，为全球健康与环境保护贡献力量，携手共创可持续发展的美好未来。」APEL 主席钟伟强博士于启用典礼致辞。与山湖集团建立战略合作关系，共拓大湾区水质净化及水产养殖科技新机遇广东山湖集团有限公司（「山湖集团」）作为全球领先的室内空气环境处理专家，其核心产品大厦扇畅销全球六大洲，服务超过5,000万用户。十年前，山湖集团旗下公司山湖机电前胆性地投入研发智能节能养殖机械科技。2025年6月13日，APEL与山湖集团正式签署战略合作备忘录，共同进军水质净化治理及智能水产养殖领域。双方计划开发对水质净化设备、生态修复技术、智能监测系统等有较大需求的包括各类环保工程项目，如河道治理、黑臭水体整治、生态修复等环保工程市场。对新型过滤材料、水处理工艺、水质监测技术等有稳定需求包括城市污水处理厂、工业园区污水处理设施的市政污水处理市场。与政府环保部门、市政工程公司建立合作关系，参与污水处理项目的招投标，提供定制化解决方案。合作内容涵盖技术研发、市场拓展及资源共享。双方将联合开发智能水质监测系统，利用大数据及人工智能优化养殖决策，并针对环保工程、市政污水处理等市场推广高效净化技术。合作项目将深度融合山湖集团在机电设备与消毒技术的产业优势，以及APEL旗下Wisepura Aquapura智能微工厂的先进水处理专利技术。此合作为期一年，期满后可自动续约，通过双方商业及技术资源技术交流会，合作成果将率先在粤港澳大湾区推广应用，有望推动大湾区环保与水产养殖产业升级，带动产业链的升级转型，展望未来将逐步拓展至海外市场。APEL（左）与山湖集团签署战略合作备忘录。迈向「工业4.0」智能制造新时代在推动「工业 4.0」的进程上，APEL Wisepura Aquapura智能微工厂将人工智能、物联网、大数据等先进技术整合到制造流程，实现智能监控与自动化管理，提升整体运营效率与产品品质。为解决混合过程中温度急升对智能硅微囊结构和性能的影响，工厂安装了一套由物理人工智能（Physical AI）驱动的定制智能温控系统、工厂更配备人机介面（HMI）、可程式设计逻辑控制器（PLC）及在位清洗（CIP）系统，以提升生产效率与灵活性。此外，工厂引入工业物联网（IIoT）监控系统，实时监测用电情况，有效优化能源管理；同时透过及时化生产管理（JIT）有效减少仓库积压及资源浪费，全面推动智能制造的高效运营。一众嘉宾参观 APEL Wisepura Aquapura智能微工厂。健康与环境科技创新双重升级水资源是维系人类生命与生态环境健康的关键，但随着城市发展，水污染问题日益严重，对公共卫生和生态系统构成重大威胁。为改善水质，APEL 研发的Wisepura Aquapura采用了全球首创、并于 2022 年及 2024 年荣获日内瓦国际发明展一金一银奖项的多孔结构硅微囊专利技术。该技术能在与水接触时智能控释其活性物质，有效消灭逾 95%的有害微生物及耐药性细菌，同时满足多样化的应用需求。这项创新技术已广泛应用于香港多个公共基础设施，有效针对供水系统、空调系统及下水道系统中超过 30 种细菌、真菌及病毒，包括退伍军人症、手足口病原体、流感病毒及白色念珠菌等，显著减低水系统及气溶胶传播疾病的风险。此外，硅微囊系统可多次循环使用，且在使用寿命结束后亦能安全弃置，降低环境负担，为水质处理解决方案树立新标准。通过精益管理及智能制造的概念，APEL 全球首个Wisepura Aquapura智能微工厂在有限的空间内成功整合了定制的生产技术、机械自动化和数据可视化，实现灵活小批量定制生产和「工业 4.0 的 1i 成熟度水准」，为 Physical AI 的应用铺平了道路。APEL 全球首个Wisepura Aquapura智能微工厂成功整合了定制的生产技术、机械自动化及数据可视化，实现了「工业 4.0的 1i 成熟度水准」。关于APEL Wisepura Aquapura智能微工厂位于九龙湾的 APEL Wisepura Aquapura智能微工厂将实验室规模的工艺放大至中试规模，并巧妙适应香港传统多层工业建筑的空间限制，成功实现每日6吨的高效产能。生产线的核心在于其 C 形布局设计，为高效运作奠定基础。工厂配备混合系统、灌装及旋盖系统，以及智能化设置，并透过定制的管道系统连接 5 个药用级混合罐，实现全流程精益管理。针对有限空间，工厂特别配备了一台 2.5米高的自动上盖机，充分利用立面空间，展现空间利用与智能化的完美结合。智能微工厂的启用和投产，不仅大幅提升了生产效率，也加速了 APEL 与力霸水泵机械工程有限公司的合作进程，促进科研产品的市场拓展。此外，智能微工厂已获渠务署正式订单，彰显其解决方案获得高度认可，并为公司持续带来实质经济效益。为布局日本这个高度重视个人健康与环境卫生的市场，APEL 现正于大阪 The Lab.举行创新互动展览会，展示三大旗舰产品 - Wisepura水质及空气净化系统、GERMAGICTM抗菌涂层和 GERMAGICTM PET 宠物健康及护理方案，把握亚洲健康科技产业的发展机遇。关于义合控股有限公司义合控股有限公司为香港主板上市公司（1662.HK），是香港一间历史悠久的承建商，主要从事提供地基工程及隧道工程业务。此外，旗下联营公司 Windmill Street Development 于英国伯明罕发展优质物业项目。集团于 2023 年成立 Absolute Pure EnviroSci Limited （「APEL」），主要从事健康及环境创新业务，包括特种生化及生物医药产品之分销及研发业务，并先后与香港科技大学及香港科学园成立实验室。其中「香港科技大学-AP EnviroSci Ltd.环境科学健康与环境创新联合实验室」之联合实验室于 2024 年 1 月 10 日启用，而位于香港科学园之「APEL生物医药科技创新及转化商业实验室」亦于 2024 年 3 月 13 日正式启用。欲知更多有关义合控股有限公司资料，请浏览网页：http://www.yee-hop.com.hk/关于 Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited（「APEL」）为香港联合交易所主板上市公司-义合控股有限公司（香港主板上市编号：1662）的间接非全资附属公司。以改善生活品质及居住环境为使命， APEL 主要从事健康与环境科技创新的研究、开发及商业化。基于其多层次杀菌涂层技术（MAP-1），APEL 已在四个关键领域：飞机空气净化、水质净化、畜牧健康和环保建材，研发专门的应用配方，旨在应对全球迫切挑战。APEL 期待与全球研究人员和行业伙伴合作，推动更多健康与环境科技创新。欲知更多有关 APEL 资料，请浏览网页：https://apesl.com/传媒如有查询，请联络：AJA (IR & Communications)庾婉华电话：+852 9500 4443电邮：avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

业绩亮点- 收入增长7.4%至15.8亿港元- 来自持续经营业务的溢利增长43.1％至3.0亿港元- 净资本负债比率由12.2％下降低至8.3％- 建议派发现金末期股息每股5.50港仙及现金特别股息每股6.00港仙- 持续通过研发及策略引进授权丰富产品线- 透过提高生产设施营运效率及杠杆，促进运营效率香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 从事基础药物及专科药物研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633.HK）今天公布公司及其附属公司（统称「集团」）截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。承接过去数年的稳健增长势头，雅各臣于本财政年度持续录得可观表现，纵使面对持续的宏观经济挑战，全年收入约为15.8亿港元，按年增长7.4%。持续经营业务的溢利飙升43.1%，达至3.0港亿元，充分体现集团坚守卓越营运及策略执行的成效。集团财务状况保持强健，为推动未来发展及股息回报提供坚实基础。在强劲业务表现及持续成本管理的支持下，集团于报告期内录得经调整EBITDA约5.7亿港元。净资本负债比率由12.2％降至二零二五财年末的8.3％，现金储备约为5.1亿港元，维持稳定水平。董事会建议派付现金末期股息每股5.50港仙（二零二四年财年：每股3.00港仙）及现金特别股息每股6.00港仙（二零二四年财年：无）。包括已派付的现金中期股息每股3.50港仙，二零二五财年的现金股息合共每股15.00港仙（二零二四财年：每股5.50港仙），按年上升172.7％。多元产品组合满足不断上升的医疗需求集团于二零二五财年的销售增长受多项因素推动。香港经历漫长的流感季节，加上多种呼吸道病原体同时活跃，带动对伤风感冒药物的需求大幅上升。人口老化，加上糖尿病及高血压等慢性疾病高发，以及精神健康需求日益增加等，进一步推升医疗需求的趋势。此外，公共卫生计划提高了公众对预防保健及早治疗的意识，增加对药物和就诊需求。在这些因素共同作用下，集团整体业务于报告期内维持销售增长。凭借丰富的基础药品及专科药物组合，集团继续具备优越的条件，满足香港不断增长的医疗需求，而透过高效的供应链，集团能够提供具成本效益的治疗选择，进一步巩固其作为香港值得信赖医疗服务供应商地位。持续推进研发与拓展专科药物组合集团于报告期内持续推进研发管线扩充，贯彻产品组合拓展战略。截至二零二五年三月三十一日，集团的研发项目包括219项处于不同开发阶段的产品。为扩大专科药物组合，集团与多家国际药厂签订授权协议，引进20项高效药物，涵盖自身免疫性疾病、肿瘤、心血管疾病、神经疾病及罕见病等多个治疗领域。这些新增药物具有出色的临床表现和市场潜力，不仅支持集团持续增长，更体现集团致力以创新疗法改善患者生活质量的承诺。以创新科技提升治疗成效集团持续扩大三氧化二砷口服液（Arsenol）的市场覆盖，该产品用于治疗急性早幼粒细胞白血病（APL），由集团与香港大学联合开发。临床试验显示，该疗法的存活率为97%，分子学缓解达100%，因而获美国食品药品监督管理局及欧洲药品管理局认定为罕见病用药。全球第三期试验将于二零二六年开始，目标是于二零二八年获上市批准。集团亦于二零二五年二月二十日达成另一重大里程碑 - 与上海复星医药（集团）股份有限公司及Fosun Kairos Biotechnology Inc. 合作，推出CAR-T疗法Axicabtagene Ciloleucel (商品名：Yikaida) 的供应链协调服务。此疗法专为治疗弥漫性大B细胞淋巴瘤而设，并已获发先进治疗产品（ATP）物流牌照，标志着集团在下一代癌症疗法领域迈出重要一步。智能生产驱动产能为配合集团提升制造能力的策略目标，集团旗下公司正美药品有限公司（Jean Marie Pharmacal Co. Limited）已于二零二五年二月于大埔创新园展开全新制药设施的建设工作。在香港政府「新型工业加速计划」的支持下，该厂房将配备十条智能生产线，用于生产无菌眼药水、固体剂型药物及口服液，通过AI、机器人及实时数据分析，提升生产效率及质量水平。试产计划预计于二零二六年底展开，重点生产专科治疗药物，针对未被满足的医疗需求。此项策略性投资不仅巩固本集团的行业领导地位，更有助推动香港发展成为先进药业制造枢纽。雅各臣主席及行政总裁岑广业先生表示：「二零二五财年对雅各臣而言是充满意义的一年，再次印证我们策略的前瞻性、团队的坚毅与投入，以及持份者对我们的信任。这些坚实基础，持续巩固我们作为香港仿制药市场领导者的地位。展望二零二六年，我们对业务前景充满信心。随着医疗政策改革推进，以及人口老化与慢性病带动药物需求上升，将持续推动基础药物市场增长。凭借强大的产品线、不断拓展的合作伙伴关系，以及数码创新，我们已具备有利优势，把握增长机遇，为集团业务创造可持续价值。」关于雅各臣科研制药有限公司（股份代号：2633）雅各臣是本地领先的医药公司，拥有垂直整合的业务，包括基础药物及专科药物的研发、生产、分销、销售及物流。作为本地主要的非专利药供货商，集团在香港私营及公营领域，具有最广泛的销售及分销的市场覆盖，并积极向策略性选择的亚洲市场伸延扩展。集团于香港设有9间PIC/S GMP认证的非专利药生产设施，并在各种治疗药物类别中拥有广泛的产品组合与享有优越市场地位。同时，集团一直致力透过增加各种高增值产品，策略性地扩大其非专利药的产品组合。扎根香港，集团已于中国、澳门、台湾及柬埔寨开设营运子公司，建立区域性商业平台，以把握亚太区及大中华地区的市场潜力。而自 2017 年 6月 1 日，集团获纳入 MSCI 香港微型股指数成份股。更多详情请浏览臣科研制药有限公司网站： http://www.jacobsonpharma.com Copyright 2025 亚太商讯 via SeaPRwire.com.

- 「创业快綫」终极决选10间优胜初创顺利诞生，绿创能源有限公司夺得「环境、社会、企业管治大奖」，安神生物科技有限公司夺得「我最喜爱初创大奖」- 「创业快綫」终极决选日邀请到逾200名业界人士参与，助初创建立人脉及增加曝光，持续推动本港创业生态圈发展- 本届优胜初创业务主要集中于健康科技，亦有多间来自绿色科技、智慧城市及人工智能等领域香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 香港贸易发展局（香港贸发局）举办的第八届初创培育计划「创业快綫」终极决选顺利完成，10间优胜初创诞生。大会今年继续设有「环境、社会、企业管治大奖」(ESG Award)，表扬最具可持续发展及社会效益的初创企业，最终由绿创能源有限公司嬴得此奖项。至于现场观众一人一票选出的「我最喜爱初创大奖」，则由安神生物科技有限公司夺得。10间优胜初创将可参与一系列由贸发局组织的本地及海外的商贸活动，全面建人脉、拓市场、增曝光、觅伙伴。贸发局全力支援及推动初创企业发展，协助他们进军海外及内地市场，推广香港创科优势。香港贸发局商品贸易及创新总监兼对外事务总监黄燕表示： 「『创业快綫』作为香港贸发局的旗舰初创培育计划，一直推动本港最具潜力及创新的科技初创茁壮成长，致力协助本地初创提升实力及建立人脉，开拓新市场同时寻找商业及融资伙伴，并提升品牌知名度。自2018启动计划以来，我们已协助70间本地初创提升规模，同时扩展业务至海外市场，不少已取得卓越成就及赢得国际奖项，得到重大投资及建立重要的商业伙伴关系，充份体现这个平台加速推动香港初创成功发展。」第八届「创业快綫」报名公司超过200间，反应踊跃。十间优胜初创业务主要集中于健康科技，亦有多间来自绿色科技、智慧城市及人工智能等领域。今年「创业快綫」终极决选日吸引逾200位业界人士参与，包括一众投资者及商界领袖，现场亦设有初创展览，由「创业快綫」入围初创向与会人士进行业务介绍。贸发局将为优胜初创提供多元化商贸交流及配对活动晋身「创业快綫」最后20强的初创，在今天的终极决选上简介业务及创业理念，在现场接受评判的即场提问及评分，最终胜出的10间优胜初创分别为：ACTuWISE Limited、Decennium Platforms Limited、安神生物科技有限公司、Digitoe Limited、世美拉有限公司、汤宏健康科技有限公司、Firefilm Group Limited、艾柏轮科技有限公司、Entoptica Limited及绿创能源有限公司。（请按此下载完整得奖名单及初创简介）香港贸发局将为优胜初创安排一系列的交流考察及推广活动，与潜在投资者、买家和合作伙伴会面。评判赞赏优胜初创紧贴市场发展及决选表现评判之一阿里云(亚太北区)资深顾问车品觉表示：「每届新入选的初创都给我们带来惊喜，面对AI迅速发展，不少企业都迅速将AI融入实体业务，可见本地初创人才紧贴市场趋势，同时具备创新思维及一定实力。」另一评判香港初创企业协会主席杜伟樑亦表示：「本届参赛初创质素颇高，提供的产品及服务牵涉不同科技领域，特别是在人工智能、绿色科技和医疗创新等方面。我们乐见新一代初创在创新及科技各范畴都持续推陈出新，为社会整体发展出一份力，展现出无限潜力和创造力。香港初创持续蓬勃增长，去年香港初创企业已达4,694间再创新高，显示香港的营商吸引力有增无减，继续是设立初创的理想地点，前景亮丽，相信今年的优胜初创将可透过『创业快綫』获得更多拓展市场及建立人脉的宝贵发展机会。」「创业快綫」助初创取得公司投资及合作机会「创业快綫」为初创提供全面的宣传机会，优胜初创企业将可亲身参与内地及海外的展览会，以及与本地及世界各地的投资者会面接洽等，从而了解更多行业动态、海外市场趋势及投资者取向，以建立商脉和拓展市场及业务。上届优胜初创之一途龄科技(Libpet Tech)最近更完成了300万美元的种子轮融资，筹集所得资金将用于技术升级及拓展国际市场。途龄科技行政总裁徐华峰表示：「参加『创业快綫』成功为公司增加曝光及提升品牌知名度，获得不少潜在客户及投资者关注，在此十分感谢投资者对公司的信心。公司将携手公私营合作伙伴，将机器人技术融入日常生活，推动以人为本的智慧出行。」第四届「创业快綫：国际篇」12月举行 全球初创大比拼香港贸发局一直致力加强本地与海外创业生态圈的交流，巩固香港致力作为亚洲创科枢纽的竞争优势。于2022年首度举行的「创业快綫：国际篇」，过去三届吸引环球各地如澳洲、法国、德国、日本、韩国、土耳其、新加坡、阿联酋及美国等地的初创报名。第四届「创业快綫：国际篇」今年将继续在12月初的「创业日」举行，协助胜出的海外初创落户香港，并透过香港的平台探索大湾区及其他内地市场。「创业快綫」网页：https://portal.hktdc.com/startupexpress/tc/图片下载：http://bit.ly/4jPwedc10间「创业快綫」优胜初创企业顺利诞生，得奖初创代表与评判及嘉宾一起合照。后排由左至右为：阿里云（亚太北区）资深顾问车品觉、兴迅集团主席兼董事总经理张益麟、道源资本集团首席执行官陈甄灏、香港贸发局商品贸易及创新总监兼对外事务总监黄燕、Betatron Venture Group管理合伙人兼执行长Matthias Knobloch、PRD初创投资主席汤雷、香港初创企业协会主席杜伟樑。「创业快綫」终极决选请来中小学生到场展示不同科创方案，由2023年优胜初创 Big Bang Academy 联合创办人唐蒨怡提供指导及颁发奖状。「创业快綫」终极决选邀请逾200名业界人士参与，让初创与投资者和商界领袖等一起交流。「创业快綫」终极决选现场设有初创展览，入围初创为与会者介绍公司业务。香港贸发局新闻中心：http://mediaroom.hktdc.com/tc传媒查询新闻界如有查询，请联络香港贸发局传讯及公共事务部：苏显博 电话：(852) 2584 4049 电邮：stanley.hp.so@hktdc.org黄家欣 电话：(852) 2584 4524 电邮：katy.ky.wong@hktdc.org张希汶 电话：(852) 2584 4272 电邮：serena.hm.cheung@hktdc.org刘茸 电话：(852) 2584 4472 电邮：clayton.y.lauw@hktdc.org香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。 Copyright 2025 亚太商讯 via SeaPRwire.com.

With the Department of Labour Peninsular Malaysia’s approval, the Ria Payroll Management System, coupled with the Ria Wallet and Prepaid Card Program, in collaboration with Mastercard, aims to promote financial inclusion among unbanked migrant workers throughout Malaysia, offering employers a secure and compliant way to manage their payroll needs.KUALA LUMPUR, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Ria Money Transfer (“Ria”), a global leader in the cross-border money transfer industry and business segment of Euronet Worldwide, Inc. (NASDAQ: EEFT) has been officially approved by the Department of Labour Peninsular Malaysia (JTKSM) for the disbursement of digital wage payments via the Ria Wallet. By streamlining wage distribution through digital means, the Ria Prepaid Card Program, in collaboration with Mastercard, provides an omni-channel solution to employers who may struggle with conventional banking access for their workforce.The Ria Wallet facilitates various financial activities such as depositing funds, withdrawing cash from ATMs, paying bills, and conducting domestic and international transfers. Customers will also be able to make payments in millions of locations in Malaysia via QR payment linked to DuitNow. In addition, the Ria Wallet streamlines payroll management for Malaysia-based companies throughout industries heavily dependent on migrant workers, including construction, agriculture, and manufacturing.According to the International Organization of Migration (“IOM”), migrants represent an estimated 15.3% of Malaysia’s total workforce, many of whom are unbanked. The Ria Wallet addresses the challenges faced by both workers and employers in the country's cash-centric payment landscape.Ria’s presence in Malaysia since 2001 has positioned Ria as one of the leading players in the money transfer industry. Leveraging its strong physical network of 624,000 locations worldwide and its presence in nearly 200 countries and territories, Ria aims to provide a diverse and seamless service experience to all customers.Espen Kristensen, Ria Money Transfer’s Managing Director Asia Pacific, expressed his excitement for the expansion of Ria's service portfolio in Malaysia. He emphasized, “We understand the challenges employers in Malaysia face when it comes to managing wages for their workers. Through the Ria Wallet, companies will be able to benefit from a digital solution that improves transparency and compliance across their operations”.In collaboration with Mastercard, The Ria Prepaid Card Program underscores the company’s commitment to driving positive social impact through the financial empowerment of different communities worldwide. About Ria Money TransferRia Money Transfer, a business segment of Euronet (NASDAQ: EEFT), delivers innovative financial services including fast, secure, and affordable global money transfers. With the world’s largest cross border real-time money movement network, Ria moves money where it matters. Bridging the gap between digital and physical spaces, Ria’s omnichannel products and services provide unprecedented consumer choice, including real-time payments, mobile wallets, currency exchange, home delivery, and cardless ATM payouts. Ria’s global infrastructure, powered by the Dandelion real-time, cross-border payments network, facilitates financial access to customers, agents and partners alike. By creating new market opportunities and promoting economic growth around the world, Ria opens ways for a better everyday life. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE / INDIA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Asia Research & Engagement (ARE), a leading sustainability-focused consultancy and capital markets engagement firm, has expanded its India team with two senior appointments: Shishir Soti, Director, Global Operations and Partnerships and Arun Kumar, Strategic Advisor – Power Markets and Technology Innovation.Founded in 2013 and headquartered in Singapore, ARE works across Asia’s key economies – including China, India, and Japan – to drive sustainability outcomes through the alignment of capital markets, corporate strategy, and policy. India’s expanding influence in energy, agriculture, and capital markets makes it not just a domestic focus but a regional anchor for accelerating Asia’s net-zero transition.“India is already making bold strides on its decarbonisation journey,” said Benjamin McCarron, Founder & Managing Director, ARE. “Expanding our footprint here strengthens our ability to connect investor expectations and corporate ambition across the region, from Tokyo to Bangkok to Singapore. India’s scale and innovation are pivotal to designing future-fit systems across all of Asia.”Shishir Soti brings more than 25 years of experience to ARE, having held senior positions in banking and financial services at institutions including Standard Chartered and ICICI Bank, as well as senior roles at environmental groups such as the Shakti Sustainable Energy Foundation and Environmental Defense Fund. At ARE he will help deepen the integration of India into ARE’s regional programmes on financed emissions, sustainable food systems, and transition financing. He will also spearhead stakeholder engagement and fundraising strategy for ARE’s India programmes, advancing efforts to align Indian corporates and banks with net-zero goals.“India’s ambition to reach net-zero by 2070 has implications far beyond its borders,” said Soti. “Its energy and agricultural transitions will shape supply chains, investment flows, and climate ambition throughout Asia. I’m proud to support ARE’s work connecting policy, capital, and corporate action at this critical intersection.”Arun Kumar joins ARE with more than 25 years of experience in power markets, technology, and strategy, having held leadership positions at PTC India, HSBC Securities, KPMG and CRISIL where he was consistently ranked among India’s top energy analysts. He will provide strategic insights into regulatory trends, market innovation, and grid decarbonisation.“ARE’s investor-informed approach has already helped shift conversations in China, Japan, and Southeast Asia,” said Kumar. “India’s power market is on the cusp of transformation, and I look forward to helping shape the trajectory through collaborative engagement and technology foresight.”Soti and Kumar will work closely with Rituj Sahu, Director – Protein Transition (India), who has been leading ARE’s work on food systems, climate finance, and impact stewardship in India since 2022. Their collective expertise positions ARE to deepen its regional impact across three core pillars: Energy transition and financed emissions engagement with corporates and banks; Sustainable food and agriculture systems, with a focus on the protein transition; Capital mobilisation, bridging global finance with local sustainability outcomes.The India expansion complements and strengthens ARE’s ongoing work in Singapore, China, Taiwan, Japan, and Thailand – creating a more connected and coordinated platform for sustainable transformation across Asia.“To solve regional sustainability challenges, we need local intelligence, regional coordination, and global capital alignment,” added McCarron. “India is integral to the systems change ARE is driving across the region.”About Asia Research & Engagement (ARE)Creating change through investor-backed engagement. ARE's pioneering approach fills an engagement gap to bring leading investors into dialogue with Asian-listed companies. ARE currently works with investors representing US$10trillion. ARE covers Asian-listed companies from the financial sector, energy-related industries, and food value chains, seeking to advance a sustainable and compassionate Asia.For media interviews and further enquiries, please contactWani DiwakarAsia Research & Engagement (ARE) wani.diwarkar@asiareengage.com Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 20.7% to HK$782.3 million- Gross profit increased by 22.4% to HK$413.7 million- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million- The Board recommends a final dividend of HK11.5 cents per share- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns- Concentrated Chinese medicine granules (“CCMG”) remained resilient, providing a steady contribution to overall business performanceHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Despite a lackluster retail environment in Hong Kong, JBM Healthcare delivered a robust financial and operational performance in FY2025. Revenue from the branded healthcare business rose by 20.7% year-on-year to HK$782.3 million. Gross profit grew by 22.4% to HK$413.7 million, while consolidated profit attributable to equity shareholders surged 51.2% to HK$197.3 million.This significant increase in consolidated profit attributable to equity shareholders was driven by robust sales of flagship brands - including Ho Chai Kung, Po Chai pills, and Flying Eagle Woodlok Oil, complemented by the resilient performance of its CCMG business. These strong results underscore the effective execution of the Group’s integrated sales and marketing strategies, and its strategic foresight in capturing growth opportunities in the branded consumer healthcare market across Hong Kong, Macau, and major cities in the Greater Bay Area.The Board recommends a final dividend of HK11.5 cents per share. Including the interim dividend of HK5.5 cents per share already paid, the total dividend for FY2025 will be HK17.0 cents per share.Solid Performance Across Core SegmentsIn the branded medicines business, sales revenue recorded strong growth of 43.2%, propelled by Ho Chai Kung’s sustained market momentum. Ho Chai Kung successfully expanded its market penetration through precisely targeted marketing initiatives that broadened its consumer base while simultaneously reinforcing brand recognition.Sales in the proprietary Chinese medicines segment grew by 5.0% against the backdrop of softened local retail sentiment of Chinese medicines and herbs, driven by the momentum of flagship brands Po Chai Pills and Flying Eagle Woodlok Oil, alongside the resilient performance of the CCMG business. Po Chai Pills enhanced brand visibility through sustained TVC placements and title sponsorship of popular television programs. Meanwhile, Flying Eagle Woodlok Oil reinforced its market position with an integrated campaign themed “Flying Eagle – The Real Master’s Choice”, highlighted by a viral “Flying Eagle Bro” billboard at Tsim Sha Tsui Star Ferry Pier, which tripled brand awareness.In the health and wellness products segment, revenue increased by 44.9%, driven by the steady growth of Oncotype DX Breast Recurrence Score Test (“Oncotype DX”), along with the expansion of our product portfolio and enhanced marketing efforts to meet consumer healthcare demands of the mass market. Oncotype DX has gained increasing recognition among healthcare professionals in Hong Kong and Macau.Capturing the Growth Potential of Cross-Border E-Commerce and TCM SectorThe Group has made steady progress in expanding its online presence on cross-border e-commerce platforms as well as strategically positioned to capitalise on the growing traditional Chinese medicine (“TCM”) sector in Hong Kong and the Greater Bay Area. The Group’s flagship stores on Tmall Global and JD.com have performed strongly, with Ho Chai Kung ranking among the top 10 overseas medicines during the 2024 Double 11 sales event. To drive sustainable growth, the Group is also diversifying into new categories while enhancing both its B2B and B2C sales networks.Strategic Acquisition of Tin Hee TongIn April 2025, the Group completed the acquisition of a 90% stake in Tin Hee Tong Medicine Factory, Limited, whose flagship product, Tin Hee Tong Tin Hee Pills, is a well-recognised brand in Hong Kong and mainland China, particularly among female consumers for its efficacy in regulating the menstrual cycle and supporting reproductive health. The acquisition expands the Group’s proprietary Chinese medicine portfolio and creates synergies by integrating Tin Hee Tong’s brand with the Group’s manufacturing and marketing strengths. Leveraging its expertise in brand management, the Group will launch a comprehensive marketing campaign to boost awareness, enhance engagement, and broaden distribution.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, “Amid the challenging retail environment, we delivered strong financial and operational performance, driven by our robust portfolio, the enduring appeal of our flagship brands, and our unwavering focus on operational excellence.”“Looking ahead, we remain committed to disciplined growth and operational excellence. With rising health awareness, increasingly sedentary lifestyles, and an ageing population continuing to fuel demand, we are well-positioned to capitalise on growth opportunities in the consumer healthcare sector. We will continue to sharpen our brand management capabilities, strengthen our core brand equity, expand our product offerings, and extend our market reach.”About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Tin Hee Tong Tin Hee Pills, Flying Eagle Woodlok Oil), Tong Tai Chung Woodlok Oil, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

业绩亮点- 收益增长20.7%至7.8亿港元- 毛利上升22.4%至4.1亿港元- 权益持有人应占综合溢利增长51.2%至1.97亿港元- 董事会建议派发末期股息每股11.5港仙- 凭借有效的品牌管理，旗舰品牌何济公、保济丸和飞鹰活络油实现强劲增长- 浓缩中药颗粒业务表现强韧，为整体业务表现提供稳定贡献香港，2025年6月12日 - (亚太商讯 via SeaPRwire.com) - 健倍苗苗（保健）有限公司（「健倍苗苗」或「公司」；股份代号：2161，连同其附属公司统称「集团」）为香港品牌保健品的领先营销商及分销商，集团今天公布截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。尽管香港零售环境疲软，健倍苗苗于二零二五财年的财务与营运表现仍然出色。集团品牌医疗保健业务的收益按年增长20.7%至7.8亿港元。毛利增长22.4%至4.1亿港元，权益持有人应占综合溢利飙升51.2%至1.97亿港元。权益持有人应占综合溢利大幅增长主要来自旗舰品牌的强劲销售表现，当中包括何济公、保济丸与飞鹰活络油，以及浓缩中药颗粒业务的稳健表现。这一优异表现，显示本集团成功落实整合的线上与线下营销策略，并体现集团的前瞻性市场触角，有效地把握香港、澳门及大湾区主要城市品牌消费健康市场增长机遇。董事会建议派发末期股息每股11.5港仙。包括已派付的中期股息每股5.5港仙，二零二五财年的股息总额为每股17.0港仙。各个核心业务表现卓越在何济公持续销售势头的带动下，品牌药分部的收益录得43.2%的强劲增长。何济公透过精准的市场营销计划扩大市场渗透率，成功扩大消费群体，同时进一步巩固品牌的知名度。在本港中成药及中药材的零售销售放缓的背景下，集团的品牌中药分部仍实现5.0%的增长。此增长主要来自旗舰品牌保济丸及飞鹰活络油的强劲表现，以及浓缩中药颗粒业务的稳健支持。保济丸通过持续的电视广告投放和冠名赞助电视人气节目，进一步提高品牌知名度。与此同时，飞鹰活络油透过以「飞鹰至系真王道」为主题的宣传计划强化市场地位，使其品牌知名度提升三倍，当中位于尖沙咀天星码头的「飞鹰哥」广告板更成功引起热议，迅速在网上疯传。健康保健品分部的销售收益增长44.9%，动力来自安可待乳癌肿瘤基因检测 (「Oncotype DX」)的稳健表现，加上产品组合扩展及加强推广，有效回应大众对健康产品日益增长的需求。Oncotype DX日益受到香港及澳门的医疗机构及医护专业人士的认可。把握跨境电子商务及中医药市场的增长潜力集团在拓展线上业务方面取得稳步进展，尤其是跨境电子商务平台，同时策略性地进行部署，把握香港及大湾区持续增长的传统中药行业机遇。集团在天猫国际和京东的旗舰店表现强劲，何济公于2024年双11期间位列十大海外药品畅销榜。为了推动可持续增长，集团正丰富多元化产品组合，同时加强B2B和B2C的销售网络。策略性收购天喜堂二零二五年四月，集团完成收购天喜堂药厂有限公司90%的股权，其旗舰产品「天喜堂天喜丸」于香港及中国内地享有极高的品牌知名度，特别受到女性消费者青睐，因其在调节女性生理周期及促进生殖健康方面具显著功效。这项收购进一步丰富了集团的品牌中药产品组合，并透过整合天喜堂品牌与集团现有的生产与营销能力，创造显著的协同效应。集团将凭借在品牌推广方面的丰富经验，开展全方位的市场推广计划，以提升该品牌知名度，加强与消费者的互动，以及扩展分销网络，进一步拓展客户基础。健倍苗苗行政总裁黄一伟先生表示：「面对零售环境的种种挑战，我们依然交出亮丽的财务及营运成绩，这有赖于我们多元而稳健的产品组合、旗舰品牌持久的市场吸引力，以及我们对卓越营运的不懈追求。展望未来，我们将继续秉持稳健增长与卓越营运的原则。随着健康意识提升、久坐的生活模式普及以及人口老龄化持续带动需求，我们已做好充分准备把握消费保健行业的增长机遇。我们将持续强化品牌管理能力，巩固核心品牌价值，扩展产品组合，并扩大市场覆盖范围。」有关健倍苗苗（保健）有限公司 （股份代号：2161）健倍苗苗是设于香港的品牌医疗保健品推广及分销公司，产品据点遍及大中华、东南亚及其他选定国家。集团拥有丰富的行销专业知识并具备深厚的制药背景，秉承产品功效和品质至上的优良传统，在行业内定位独特，致力于满足消费者的保健需要。作为本地领先的品牌医疗保健品运营商，集团拥有一广泛系列品牌医疗保健品，包括品牌药、品牌中药及健康保健品，其中包括「保济丸」、「何济公止痛退热散」、「天喜堂天喜丸」、「飞鹰活络油」、「唐太宗活络油」、「十灵油」、「镇痛霸祛风活络油」等家喻户晓的传统品牌。而自2021年 5月27日，集团获纳入 MSCI 香港微型股指数成份股。有关集团详情，请浏览：www.jbmhealthcare.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

- On the Final Pitching Day of Start-up Express, 10 winners were selected, with xxx and AniTech Limited receiving the ESG Award and the My Favourite Start-up Award respectively- More than 200 industry players attended, helping start-ups to establish connections and increase exposure, and continue to promote Hong Kong's entrepreneurial ecosystem- Majority of the 10 winners are health tech start-ups, while others represented sectors such as green tech, smart city and AI SolutionsHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - 10 start-ups were selected as winners at the eighth edition of Start-up Express, an entrepreneurship development programme organised by the Hong Kong Trade Development Council (HKTDC) which came to a successful conclusion. The ESG Award was presented to Green Vigor Limited in recognition of the best sustainable and socially impactful business solution, and AniTech Limited won the My Favourite Start-up Award as determined through audience live polling. The 10 start-ups will participate in a series of local and overseas business events organised by HKTDC to develop their profiles through building connections, exploring markets, seeking partners and enhancing brand awareness.HKTDC is fully committed to supporting and promoting the development of start-ups, helping them to expand into Mainland and international markets to showcase Hong Kong’s strengths in innovation and technology.Iris Wong, Director of Merchandise Trade and Innovation & External Relations of HKTDC said: “Start-up Express serves as the launchpad for Hong Kong’s brightest tech innovators. As HKTDC’s flagship start-up development programme, our mission is to help local tech start-ups build capability and connections, explore new markets, seek business and funding partners, and enhance their brand awareness. I am proud to share that we have already assisted 70 Hong Kong start-ups to scale-up in Hong Kong and expand into overseas markets since we first held Start-up Express in 2018. Many of these start-ups have achieved remarkable success, earning global awards, securing significant investments, and forming key business partnerships. This demonstrates how the HKTDC platform helps bring Hong Kong start-ups into the limelight and accelerate their success.”This year’s Start-up Express attracted more than 200 applications. The majority of the 10 winners are health tech start-ups while the rest represent green tech, smart city and AI solutions. Booths were also set up during the event enabling the Start-up Express finalists to showcase their businesses to all attendees and participants.Comprehensive range of networking and matching initiatives provided to winning start-upsThe 10 winners were chosen from 20 contestants during the final pitching round with each presenting their innovative business ideas and answering questions raised by the distinguished judging panel. The 10 winning start-ups are: ACTuWISE Limited, Decennium Platforms Limited, AniTech Limited, Digitoe Limited, CELLmeric Limited, RT Healthtech Co. Limited, Firefilm Group Limited, Albacastor Technology Limited, Entoptica Limited and Green Vigor Limited.Click here to download the list of winners and their company profiles.The HKTDC will arrange a series of exposure opportunities for the winning teams to interact with potential investors, buyers and partners.Judges praised the winners for their performance and awareness of market trendsOne of the judges, Herbert Chia, Senior Advisor of Alibaba Cloud (North APAC Region), said: “We are always surprised by the new start-ups in each year's awards. In the face of rapid AI development, many local start-ups have quickly incorporated AI into their business operations, showing that they are innovative, capable and also closely following the market trend.”Another judge, Jimmy Tao, Chairman of Hong Kong Startup Council, said: “The quality of this year's competition is high, with products and services covering different technologies, especially artificial intelligence, green tech and medical innovation. We are pleased to see the new generation of start-ups continue to break new grounds in innovation and technology, demonstrating their unlimited potential and creativity, thereby contributing to society’s advancement. Hong Kong's start-up scene continues to grow vigorously, with a record number of 4,694 start-ups last year, demonstrating Hong Kong's promising outlook and increasing attractiveness to do business and as an ideal to set up a start-up. We believe that this year's winning start-ups will gain valuable opportunities to expand their markets and build networks through Start-up Express.”Start-up Express helps start-ups secure investment and partnership opportunitiesStart-up Express provides extensive promotional opportunities for start-ups with winners able to take part in exhibitions in Mainland China and internationally, attend meetings with investors to learn more about the industry, market trends and investors’ preference.Libpet Tech, a Start-up Express winner in 2024, has recently completed a US$3 million seed funding, and the investment will be utilized for technology upgrades and international market expansion. Jojo Xu, CEO of Libpet Tech, said: "Participating in Start-up Express has given us more exposure and enhanced our brand awareness, as seen from the increased attention from potential customers and investors. We are grateful for the investors' confidence in our company. We will join hands with our public and private partners to integrate robotics into daily life and promote human-centric smart mobility.”The 4th Start-up Express International returns in December with global start-upsThe HKTDC has always given its full support to Hong Kong’s entrepreneurial ecosystem, helping to maintain the city’s status as a competitive business centre and hub for innovation. Start-up Express International was launched in 2022 for overseas early-stage start-ups to share the stage with local Start-up Express winners. The past three editions have attracted participants from around the world, including Australia, France, Germany, Japan, Korea, Turkey, Singapore, United Arab Emirates and the United States. The 4th Start-up Express International will return during Entrepreneur Day in December and the HKTDC will support the winners in setting up their businesses in Hong Kong and to explore the mainland and Greater Bay Area markets.Start-up Express: https://portal.hktdc.com/start-upexpress/Photo download: http://bit.ly/4jPwedcRepresentatives of the 10 winners of Start-up Express took a group photo with the judges and guests. Back row, from left to right: Herbert Chia, Senior Advisor of Alibaba Cloud (North APAC Region), Alan Cheung, Chairman & Managing Director of Grandion Group, Anthony Chan, CEO of Isola Capital, Iris Wong, HKTDC’s Director of Merchandise Trade and Innovation & External Relations, Matthias Knobloch, Managing Partner & CEO of Betatron Venture Group, Lui Tong, Chairman of PRD Angels and Jimmy Tao, Chairman of Hong Kong start-up CouncilStudents from local schools were invited to the Final Pitching Day of Start-up Express to present their innovative solutions. They were mentored by Sarah Tong, co-founder of Big Bang Academy, winner of Start-up Express 2023, who also presented the awardsMore than 200 industry players attended the Final Pitching Day of Start-up Express, giving the opportunity for start-ups to network with investors and business leadersBooths were also set up during the event, where finalists showcased their businesses to all attendees and participantsHKTDC Media Room: http://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Stanley So Tel: (852) 2584 4049 Email: stanley.hp.so@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgClayton Lauw Tel: (852) 2584 4472 Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit:www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

MUNICH, June 11, 2025 - (ACN Newswire via SeaPRwire.com) - A global energy transition is no longer optional-it's a necessity. But behind the scenes of solar and wind, another technology is entering industrial reality with far greater implications. Neutrinovoltaic technology, developed by the Neutrino® Energy Group, is not a distant concept. It's an operational platform for decentralized, 24/7 energy generation that is now expanding into mobility, aerospace, marine systems, and even high-security communications.Neutrinovoltaic Energy: Quiet, Infinite, Everywhere. Neutrinovoltaic technology converts the kinetic energy of neutrinos and other non-visible radiation into electricity. These omnipresent particles trigger atomic vibrations in a nanomaterial composed of alternating layers of graphene and doped silicon. The resulting resonant frequency is transformed into direct current. Far from ambient energy scavenging, this is a controlled, scalable generation method already powering advanced applications.Power Without Fuel: The Neutrino Power CubeThe Neutrino Power Cube is a compact, modular, and emission-free energy system delivering 5 to 6 kilowatts of continuous power. Weighing just 50 kilograms, it operates silently and autonomously, independent of weather or location. With no fuel, no combustion, and no grid connection required, the Cube holds the potential to decentralize energy infrastructure and become a cornerstone of clean, off-grid power generation worldwide.Autonomous Mobility: The Pi CarThe Pi Car applies neutrinovoltaic integration to electric vehicles. Instead of relying on traditional charging infrastructure, the Pi Car generates power continuously by embedding neutrinovoltaic materials into structural components like the body panels and roof. After an hour in ambient conditions, the vehicle can achieve up to 100 kilometers of additional range. Collaborators include Simplior Technologies for AI-based energy optimization, C-MET Pune for materials development, and SPEL Technologies for battery integration. The concept also supports retrofitting existing EV platforms to enhance range and energy independence.Flight Beyond Limits: Pi FlyPi Fly is Neutrino® Energy Group's aeronautics program, developing UAVs powered by onboard neutrinovoltaic systems and supercapacitor storage. Current prototypes include multirotor and flying wing models. The next phase targets autonomous VTOL aircraft for cargo delivery. Supporting this effort are mobile hydrogen refueling units, also powered by neutrinovoltaics, enabling off-grid aviation infrastructure.Maritime Transformation: Nautic PiNautic Pi brings this energy platform to the sea. Neutrinovoltaic-powered marine vessels are under conceptual development, allowing autonomous navigation without onboard fuel or external charging. The system is particularly suited for long-duration missions, remote operations, and submersible platforms.Communication Breakthrough: Project 12742Finally, Project 12742 explores neutrino-based data transmission. Unlike radio signals, neutrinos pass through dense materials with minimal interference. This allows for real-time, secure global communication even through rock, oceans, or planetary bodies-an enormous leap for high-security and interplanetary data systems.As governments and industries seek viable decarbonization paths, the Neutrino® Energy Group is no longer just proposing solutions-it's deploying them. With a multidisciplinary team of hundreds of researchers, engineers, and scientists from over 40 countries, strategic alliances, and a growing portfolio of high-impact applications, neutrinovoltaic technology isn't coming-it's already here. And it's conquering the world.Neutrino Energy GroupNeutrino Scientific BoardHolger Thorsten Schubart - CEOWebsite: www.neutrino-energy.comContact InformationHolger Thorsten SchubartCEO and member of the Scientific Advisory Boardoffice@neutrino-energy.com+493020924013Related Videohttps://www.youtube.com/watch?v=LiswrRR8H2QSOURCE: Neutrino Energy Group Copyright 2025 ACN Newswire via SeaPRwire.com.

尼黑, 2025年6月11日 - (亚太商讯 via SeaPRwire.com) - 全球能源转型已不再是可选项，而是势在必行。然而，在太阳能和风能的背后，一项具有更深远意义的技术正逐步走入工业现实。由 Neutrino® 能源集团开发的中微子光伏技术，不再是遥不可及的概念，而是已投入运行的分布式全天候能源生成平台，并正扩展至交通、航空航天、海洋系统，甚至高安全通信领域。中微子光伏技术 通过将中微子及其他不可见辐射的动能转化为电能实现发电。这些无处不在的粒子会激发一种由石墨烯与掺杂硅交替层构成的纳米材料中的原子振动，产生共振频率并被转换为直流电。这种方式远非环境能量“采集”，而是一种可控、可扩展的发电方法，已被用于多项先进应用。无需燃料的电力：中微子能量方块中微子能量方块是一种紧凑型、模块化、无排放的能源系统，可持续输出5至6千瓦电力。设备仅重50公斤，运行时安静、无需人工干预，且不受天气与地理位置影响。它不依赖燃料、不发生燃烧、无需接入电网，具备去中心化能源基础设施的潜力，有望成为全球清洁、离网发电的重要支柱。自主移动出行：Pi CarPi Car 将中微子光伏技术应用于电动汽车领域。它不依赖传统充电基础设施，而是通过将中微子光伏材料嵌入车身面板、车顶等结构部件中，实现持续发电。在常规环境条件下，仅需一小时即可为车辆带来最多达100公里的额外续航里程。合作伙伴包括负责基于人工智能的能源优化的 Simplior Technologies、从事材料研发的 C-MET Pune，以及提供电池集成方案的 SPEL Technologies。该技术理念还支持对现有电动车平台进行改造，从而提升续航能力并实现能源独立。突破飞行极限：Pi FlyPi Fly是 Neutrino® 能源集团的航空项目，致力于开发由机载中微子光伏系统和超级电容存储供能的无人飞行器（UAV）。目前的原型机包括多旋翼和飞翼机型。下一阶段的目标是开发用于货物运输的自主垂直起降（VTOL）飞行器。为支持该项目，还配备了由中微子光伏技术供能的移动氢燃料补给装置，推动离网航空基础设施的发展。海洋革新：Nautic PiNautic Pi 将这一能源平台拓展至海洋领域。采用中微子光伏技术驱动的船舶目前正处于概念开发阶段，目标是实现无需燃料或外部充电的自主航行。该系统尤其适用于长时间任务、远程作业及水下平台。通信突破：12742号项目最后，12742号项目探索基于中微子的数据信号传输。与无线电信号不同，中微子可轻易穿透密集介质，几乎不受干扰。这项技术使得即便是在岩层、海洋，甚至是行星体之间，也能实现实时、加密的全球通信——为高安全级别通信及星际数据传输带来了巨大飞跃。在全球政府与产业寻找切实可行的脱碳路径之际，Neutrino® 能源集团不再只是提出解决方案，而是在切实推进落地。该集团汇聚了来自40多个国家的数百位研究人员、工程师和科学家，构建了跨学科团队，并与多方建立战略联盟，持续拓展高影响力应用领域。中微子光伏技术不再是未来的设想，它已经到来，正在征服世界。Neutrino Energy GroupNeutrino Scientific BoardHolger Thorsten Schubart - CEOWebsite: www.neutrino-energy.com联系信息Holger Thorsten SchubartCEO and member of the Scientific Advisory Boardoffice@neutrino-energy.com+493020924013相关视频https://www.youtube.com/watch?v=LiswrRR8H2Q来源: Neutrino Energy Group Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Jun 11, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) Design Gallery continues to champion original Hong Kong designs. The annual “Love HK” exhibition returns from 11 June to 6 July, in partnership with STICKYLINE, a prominent creative team in Hong Kong, and will debut their latest artwork, “The Carved Duo”, at the Design Gallery Wan Chai shop, featuring large-scale artistic paper sculptures that capture the essence of a traditional dragon and phoenix grand hall.Carved dragon and phoenix statues were iconic decorations in Hong Kong’s banquet halls during the 1970s. STICKYLINE reimagines these symbols through contemporary geometric paper sculptures, incorporating pixel-like grid patterns into the Design Gallery’s window. This artwork retains the auspicious meanings of the dragon and phoenix while refining their forms, exploring how cultural heritage can evolve within modern contexts.STICKYLINE’s co-founder Mic Leong said, “We are thrilled to collaborate with the HKTDC Design Gallery on the ‘Love HK’ exhibition. In line with the theme, we have created paper sculptures inspired by the traditional dragon and phoenix grand halls found in old restaurants which were used to symbolise the city’s economic boom and opulence. Although modern restaurants have phased out such designs, these motifs are resurfacing in unexpected ways, such as tattoo art, wedding backdrops, and avant-garde photography, reflecting younger generations’ reinterpretation of tradition. Through this piece, we aim to revive the collective memories of old-school restaurants and showcase Hong Kong's unique charm.”In addition to the dragon and phoenix installation, the main entrance of the Design Gallery features a playful paper sculpture of the word “HEY”. Soilworm Lai, Co-Founder, STICKYLINE, explained, “‘HEY’ is a phonetic nod to the word ' (double happiness)’. We aspire to merge modern elements with the traditional dragon and phoenix theme, offering a friendly greeting to visitors.”Curated selection of Hong Kong-themed productsDuring the exhibition, the Design Gallery will feature a curated selection of Hong Kong-themed products, including AMAZING STUDIO Neon Light Hong Kong Metal Badge Pin, CAMEL Modern Hong Kong Culture Glass Vacuum Flask, IRON WORKSHOP Hong Kong Silk Scarf Map, and PLAYFUL SOCKS Dragon Phoenix Happiness Socks.Share on social media for shopping discountVisitors can enjoy an additional 10% discount on purchases during the exhibition by taking photos of the exhibits and sharing these on social media, tagging @HKTDC Design Gallery.Design Gallery Love HK x STICKYLINE – “The Carved Duo” ExhibitionDate11 June – 6 July 2025VenueHKTDC Design GalleryG/F, Hong Kong Convention & Exhibition Centre, 1 Harbour Road, Wan Chai, Hong KongOpening hoursMonday – Sunday & Public Holidays: 10:30am – 7:30pmEnquiries2584 4146 / 2584 4149Websitehttps://hkdesigngallery.hktdc.com/Social MediaFacebook: www.facebook.com/HKTDC.DesignGalleryInstagram: www.instagram.com/hktdc_designgalleryPhoto download: https://bit.ly/4dXb9fzThe HKTDC Design Gallery annual “Love HK” exhibition returns from 11 June to 6 July, in partnership with STICKYLINE, a prominent creative team in Hong Kong, to debut their latest artwork, “The Carved Duo”, at the Design Gallery Wan Chai shop, featuring large-scale artistic paper sculptures that capture the essence of traditional dragon and phoenix grand hallSTICKYLINE, founded in Hong Kong by creative designers Mic Leong (left) and Soilworm Lai (right), creates unique, large-scale polyhedral sculptures that showcase the complexity of creative engineering, mathematics and geometric structuresCurated selection of Hong Kong-themed productsAMAZING STUDIONeon Light Hong Kong Metal Badge PinPrice: HK$78CAMELModern Hong Kong Culture Glass Vacuum FlaskPrice: HK$439IRON WORKSHOPHong Kong Silk Scarf MapPrice: HK$370KONSEPTRemote Control Block Hong Kong TramPrice: HK$799PLAYFUL SOCKSDragon Phoenix Happiness SocksPrice: HK$99YI-MINGPOLA Hong Kong Print Chinese Folding FanPrice: HK$168WebsiteHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Serena CheungAgnes WatTel: (852) 2584 4272Tel: (852) 2584 4554Email: serena.hm.cheung@hktdc.orgEmail: agnes.ky.wat@hktdc.orgAbout STICKYLINESTICKYLINE, founded in Hong Kong in 2011 by creative designers Mic Leong and Soilworm Lai, creates unique, large-scale polyhedral sculptures that showcase the complexity of creative engineering, mathematics and geometric structures. They transform two-dimensional planes into three-dimensional forms through a process of deconstruction and reconstruction. They have collaborated with international brands including Hermès, Ralph Lauren, and Mercedes-Benz.Discover more at: https://www.stickyline.hkAbout HKTDC Design GalleryEstablished in 1991, the Hong Kong Trade Development Council’s Design Gallery (DG) promotes Hong Kong’s creativity innovation in design. With two physical outlets in Hong Kong and Taobao and JD International online stores, DG helps Hong Kong brands connect and collaborate with buyers to grow and expand in Mainland China and beyond. The DG online shop also provides suppliers with local online sales channels. DG’s entry into the ASEAN market enables Hong Kong brands to connect with overseas consumers and buyers.Discover more at: https://hkdesigngallery.hktdc.com/About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

圣地亚哥, 2025年6月11日 - (亚太商讯 via SeaPRwire.com) - 英国国防部已与通用原子航空系统公司（GA-ASI）签署一项关于“保护者”RG Mk1遥控驾驶飞机系统的物流与维护支持合同。该合同被称为“英国保护者可用性与支持方案”（UK PASS），将为由 GA-ASI 提供、目前由英国皇家空军（RAF）操作的新型“保护者”遥控驾驶飞机系统提供持续支持。该型号的“保护者”遥控机基于 GA-ASI 的 MQ-9B SkyGuardian®平台。照片来源：英国皇家空军UK PASS 是一项直接商业销售（Direct Commercial Sale）合同，涵盖对“保护者”项目中遥控驾驶飞机（RPA）、可认证地面控制站以及仿真训练系统的支持。“这份合同标志着英国皇家空军部署‘保护者’遥控系统的重要里程碑，”通用原子公司欧洲 MQ-9B 副总裁克里斯·杜塞尔（Chris Dusseault）表示，“随着 UK PASS 合同的签订，我们可以从测试和开发阶段正式过渡到皇家空军飞行员的操作训练阶段。”UK PASS 是通用原子公司“天空守护者全球支持方案”（SkyGuardian Global Support Solutions，简称 SGSS）的一部分，SGSS 为 MQ-9B 所有用户提供支持。该方案采用共享的承包商后勤支持（Contractor Logistics Support, CLS）模式，将维护、供应管理及其他所需的支持功能所涉及的人员、物资和间接资源统一整合，供所有客户共同使用。这种方式提升了效率，并为客户降低了成本。“PASS 合同的签订是通用原子公司与英国国防部跨领域团队三年来密切合作的成果，它将一个概念转化为现实。我们为皇家空军的‘保护者’机队打造了首个同类中的可持续支持解决方案，依托的是全球通用备件池中的承包商自有库存。该合同不同于传统的备件和维修合同，而是通过多客户通用运营模式实现规模经济，”英国皇家空军无人机系统3组组长里奇·卡梅伦上校（Group Captain Rich Cameron）表示。通用原子公司的 MQ-9B 是目前世界上最先进的遥控驾驶飞机系统，具备卓越的续航能力和作战范围。MQ-9B 包括“天空守护者”（SkyGuardian）和“海洋守护者”（SeaGuardian®）两个型号，目前已向英国皇家空军（即“保护者”项目）交付多架，并获得来自加拿大 、波兰、日本海上保安厅、日本海上自卫队、台湾、印度及美国空军（用于特种作战司令部支持）的订单。MQ-9B 也曾参与多项美国海军演习，包括“北方利剑”（Northern Edge），“一体化作战问题”（Integrated Battle Problem）和“联合航行演训”（Group Sail）。关于 GA-ASI通用原子航空系统公司（GA-ASI）是通用原子公司的子公司，致力于设计和制造成熟可靠的远程驾驶航空系统（RPA）、雷达及电光和相关任务系统，包括 Predator® RPA 系列和 Lynx® 多模式雷达。GA-ASI 运营超过 800 万飞行小时，提供具备长航时和任务能力的航空平台，并集成传感器和数据链系统，以实现持续态势感知。公司还研发多种传感器控制和图像分析软件，提供飞行员培训及支持服务，并开发超材料天线。更多信息，请访问： www.ga-asi.com 。Avenger、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 均为通用原子航空系统公司在美国及其他国家/地区注册的商标。联系信息GA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101来源: General Atomics Aeronautical Systems, Inc. Copyright 2025 亚太商讯 via SeaPRwire.com.